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Voriconazole penetrated well into the pulmonary epithelial lining fluid (ELF) in lung transplant patients
receiving oral prophylaxis. The ELF concentrations exceeded those of the plasma, with an average ELF-to-
plasma ratio of 11 (8). A strong association between plasma and ELF concentrations (r2  0.95) was noted.
Adequate drug penetration to the infection site is crucial for
antimicrobial therapeutic optimization. The lungs are the most
common site of primary infection in cases of invasive aspergil-
losis (9, 14). Voriconazole has become a preferred agent for
the treatment of invasive aspergillosis (3). Despite its wide-
spread use in the management of pulmonary aspergillosis, the
intrapulmonary penetration of voriconazole has not been re-
ported in humans. Voriconazole is used routinely as antifungal
prophylaxis in some lung transplant centers; this offers an op-
portunity to study the intrapulmonary penetration of the drug,
since lung transplant recipients routinely undergo surveillance
bronchoscopy (5, 7).
This was a prospective observational pilot study. The sub-
jects were lung transplant patients, 18 years of age, who had
received at least six oral doses of voriconazole prior to a sched-
uled bronchoscopy. The Institutional Review Board approved
the study, and all patients provided written informed consent
prior to participation.
Voriconazole treatment (6 mg/kg of body weight intrave-
nously every 12 h for 2 doses followed by 200 mg orally twice
daily) was initiated immediately after transplant and continued
for approximately 4 months as standard clinical care. Bronchoal-
veolar lavage (BAL) was performed at 2, 4, and 8 weeks post-
transplant in all patients during the voriconazole prophylaxis
period. A blood sample and an aliquot of pooled BAL super-
natant were acquired for study purposes during one of these
procedures.
Total (free and protein-bound) voriconazole concentrations
were measured in the plasma and BAL supernatant by a mod-
ified high-performance liquid chromatography–electrospray ioni-
zation mass spectrometry technique (13, 18). Authentic voricon-
azole (UK-109,496) and an internal standard (UK-103,446)
were provided by Pfizer Global Research and Development
(Sandwich, United Kingdom). The standard curves were linear
(r2  0.99) over a concentration range of 0.05 to 6.0 g/ml for
the plasma and 0.001 to 0.5 g/ml for the BAL. Interday
coefficients of variation were 12.6%.
The concentrations of urea in the serum and BAL supernatant
were measured, separately, by a colorimetric method (serum,
Vitros 950 [Ortho Clinical Diagnostics, Rochester, NY]; BAL,
Urea Nitrogen Reagent [Teco Diagnostics, Anaheim, CA],
respectively). The volume of epithelial lining fluid (ELF) re-
covered in the BAL aspirate and the concentration of voricon-
azole in the ELF were calculated based on the urea dilution
method as previously reported (1, 2, 12). A two-tailed Spear-
man’s rank correlation test was applied to test for a relation-
ship between plasma and ELF concentrations.
Twelve patients were enrolled in the study, with BAL and
blood samples successfully collected from 11 patients (Table 1).
All study patients were receiving multiple concomitant medi-
cations at the time of bronchoscopy, none of which has been
documented to impact the plasma concentration of voricon-
azole (11).
The average volumes instilled and recovered during the
BAL procedure were 116 11 ml and 64 14 ml, respectively.
The average calculated ELF volume recovered was 1.4  0.7
ml, or 2% of the total lavage fluid recovered. At the time of
bronchoscopy, 2/12 patients had minimal acute rejection, and
1/12 patients had severe acute rejection.
The total voriconazole concentration in the ELF exceeded
that in the plasma in all patients studied, with a mean ELF-
to-plasma concentration ratio  standard deviation of 11  8
(Table 2). A strong association between plasma and ELF con-
centrations (r2  0.95; P  0.0001) was observed. No differ-
ences in pulmonary penetration based on the type of lung
transplantation or acute or chronic rejection status at the time
of bronchoscopy were noted.
To our knowledge, this is the first report of the intrapulmo-
nary penetration of voriconazole in humans. Although based
on a limited sample size, our data reveal that voriconazole
achieves substantial lung penetration. The physiological basis
for the higher concentration of voriconazole in the ELF than
that in the plasma is unknown and warrants further evaluation.
The highest voriconazole ELF concentrations were observed
in patients sampled at 5 to 6 h postdose (Table 2). Since
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voriconazole reportedly peaks in the plasma at 2 to 3 h follow-
ing oral dosing, this may indicate a lag time in the attainment
of peak pulmonary concentrations (11). A wide degree of vari-
ability in ELF and plasma voriconazole concentrations be-
tween patients was observed (Table 2). This was expected,
based on the nature of this type of study, the limited sample
size, and the use of different BAL sampling time points in
relation to drug administration. Furthermore, a large degree of
interpatient pharmacokinetic variability is known to be associ-
ated with voriconazole due to its nonlinear pharmacokinetics
and genetic polymorphism of cytochrome P-450 enzymes that
metabolize voriconazole (11, 15).
The ELF concentration of an antibacterial agent is consid-
ered to be a “best estimate” of the concentration at the site of
extrapulmonary bacterial infection (4, 8). However, the site of
intrapulmonary infection of Aspergillus spp. is not well defined,
and the clinical relevance of antifungal ELF concentrations is
unknown. In vitro studies demonstrate a propensity for the
conidiae and hyphae of Aspergillus fumigatus to invade and
germinate in human pneumocytes (6, 17). Thus, the sites of
pulmonary aspergillosis likely include not only the ELF but
also alveolar macrophages, pulmonary epithelial cells, and the
interstitial fluid of lung tissue.
The voriconazole ELF concentration achieved with the pro-
phylactic regimen exceeded both the MIC50 (0.25 g/ml) and
the MIC90 (1.0 g/ml) previously reported for Aspergillus spp.
(10, 16) at the time of bronchoscopy in all but two patients. The
ELF concentration in subject 9 fell below the MIC90 midway
through the dosage interval. The clinical relevance of drug
exposure in relation to the MIC of a fungal pathogen at the site
of infection is unknown at this time. Further pharmacodynamic
and clinical studies are required to identify clinically relevant
antifungal concentrations at the site of infection.
The volume of ELF recovered in the BAL aspirate is calcu-
lated based on the premise that the urea concentration in the
blood and ELF is in equilibrium. Although the ELF volume
recovered in the current study (1.4  0.7 ml) was consistent
with that reported in healthy subjects (1.7  0.2 ml), a larger
proportion of BAL fluid was determined to be ELF (2% versus
1%, respectively) (12). It is unclear whether urea contamina-
tion of the BAL fluid from other sources contributed to an
overestimation of ELF volume or whether our results depict
differences in lung transplant patients compared to healthy
subjects. Nonetheless, an overestimation of ELF volume would
result in an underestimation of the ELF voriconazole concen-
tration based on a dilutional effect (12). Finally, it must be
noted that total voriconazole concentrations (free and protein
bound) were measured in both the plasma and BAL superna-
tant. Free-drug concentrations in these compartments may be
less than those reported here.
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